CAS: 844501-00-4; (1-(Tert-Butoxycarbonyl)-1,2,3,6-Tetrahydropyridin-4-yl)Boronic Acid

结构式图片

相似化合物

286961-14-6 1451153-83-5 2746407-88-3

上下游产品

CAS号375853-82-0 1,2,3,6-四氢吡啶-4-...

合成工艺路线路线简述

  • 286961-14-6 = 844501-00-4
    反应条件:1.1 Reagents: Ammonium Acetate,Sodium Periodate Solvents: Acetone,Water; 24 H,Rt
    标题:Potent And Selective Human Neuronal Nitric Oxide Synthase Inhibition By Optimization Of The 2-Aminopyridine-Based Scaffold With A Pyridine Linker
    作者:Wang,Heng-Yen; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2016 卷标:59(10) 页码:4913-4925]

    286961-14-6 = 844501-00-4 [标题:Reaction Conditions
    标题:Development And Investigation Of A Site Selective Palladium-Catalyzed 1,4-Difunctionalization Of Isoprene Using Pyridine-Oxazoline Ligands
    作者:Mccammant,Matthew S.; Et Al
    参考文献:Chemical Science 日期:2015 卷标:6(2) 页码:1355-1361
📜N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯置于sodium Periodate,Ammonium Acetate体系中,用 水,丙酮 作为反应溶剂,化学反应 24.0H,反应生成 [1-(叔丁氧基羰基)-1,2,3,6-四氢吡啶-4-基]硼酸
参考文献:有力和选择性的人类神经元一氧化氮合酶抑制的优化基于2-氨基吡啶的吡啶连接基的支架.
标题:有力和选择性的人类神经元一氧化氮合酶抑制的优化基于2-氨基吡啶的吡啶连接基的支架.
摘要:神经元一氧化氮合酶(nnos)是治疗各种神经退行性疾病的重要治疗靶标.设计nnos抑制剂的主要挑战在于对人类的效力以及对其他nos同工型的选择性.在这里,我们报告基于2-氨基吡啶骨架与中央吡啶连接基的有效和选择性人类nnos抑制剂.化合物14J是这项研究中最有希望的抑制剂,对大鼠nnos(k I = 16 Nm)具有828倍n / E和118倍n / I选择性,对人nnos的k I值为13 Nm,具有出色的药效.具有1761倍的人类n / E选择性.化合物14J 尽管它对caco-2的通透性很小甚至没有,但在人肝微粒体中也显示出非常好的代谢稳定性,血浆蛋白结合率低,与细胞色素p450(cyps)的结合力最小.
DOI:10.1021/acs.Jmedchem.6B00273

海关参考信息

专利信息


专利号:US-11225655-B2
优先权日:2010-04-16
标题:Bi-functional complexes and methods for making and using such complexes
发明人:GOULIAEV ALEX HAAHR; FRANCH THOMAS; GODSKESEN MICHAEL ANDERS; JENSEN KIM BIRKEBAEK
权利人:GOULIAEV ALEX HAAHR; FRANCH THOMAS; GODSKESEN MICHAEL ANDERS; JENSEN KIM BIRKEBAEK; NUEVOLUTION AS
摘要:The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知